oholic Steatohepatitis (NASH)-EMEA Market Status and Trend Report 2013-2023
Report Summary
oholic Steatohepatitis (NASH)-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on oholic Steatohepatitis (NASH) industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of oholic Steatohepatitis (NASH) 2013-2017, and development forecast 2018-2023
Main market players of oholic Steatohepatitis (NASH) in EMEA, with company and product introduction, position in the oholic Steatohepatitis (NASH) market
Market status and development trend of oholic Steatohepatitis (NASH) by types and applications
Cost and profit status of oholic Steatohepatitis (NASH), and marketing status
Market growth drivers and challenges
The report segments the EMEA oholic Steatohepatitis (NASH) market as:
EMEA oholic Steatohepatitis (NASH) Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA oholic Steatohepatitis (NASH) Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Weight Loss Treatment
Insulin-Sensitizing Agents
Lipid-Lowering Drugs
Antioxidants
Other Agents
EMEA oholic Steatohepatitis (NASH) Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital
Clinics
Drug Store
Research institute
Others
EMEA oholic Steatohepatitis (NASH) Market: Players Segment Analysis (Company and Product introduction, oholic Steatohepatitis (NASH) Sales Volume, Revenue, Price and Gross Margin):
Boehringer Ingelheim
Cerenis Therapeutics
Connexios Life Sciences
Genfit
Islet Sciences
Nimbus Therapeutics
Verva Pharmaceuticals
Viking Therapeutics
Astazeneca Plc
Galmed Pharmaceuticals Ltd.
GENFIT SA
Gilead Science
Novo Nordisk
Immuron Ltd
Intercepts Pharmaceuticals
Enzo Biochem, Inc
Tobira Therapeutics, Inc.
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
oholic Steatohepatitis (NASH)-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on oholic Steatohepatitis (NASH) industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of oholic Steatohepatitis (NASH) 2013-2017, and development forecast 2018-2023
Main market players of oholic Steatohepatitis (NASH) in EMEA, with company and product introduction, position in the oholic Steatohepatitis (NASH) market
Market status and development trend of oholic Steatohepatitis (NASH) by types and applications
Cost and profit status of oholic Steatohepatitis (NASH), and marketing status
Market growth drivers and challenges
The report segments the EMEA oholic Steatohepatitis (NASH) market as:
EMEA oholic Steatohepatitis (NASH) Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA oholic Steatohepatitis (NASH) Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Weight Loss Treatment
Insulin-Sensitizing Agents
Lipid-Lowering Drugs
Antioxidants
Other Agents
EMEA oholic Steatohepatitis (NASH) Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital
Clinics
Drug Store
Research institute
Others
EMEA oholic Steatohepatitis (NASH) Market: Players Segment Analysis (Company and Product introduction, oholic Steatohepatitis (NASH) Sales Volume, Revenue, Price and Gross Margin):
Boehringer Ingelheim
Cerenis Therapeutics
Connexios Life Sciences
Genfit
Islet Sciences
Nimbus Therapeutics
Verva Pharmaceuticals
Viking Therapeutics
Astazeneca Plc
Galmed Pharmaceuticals Ltd.
GENFIT SA
Gilead Science
Novo Nordisk
Immuron Ltd
Intercepts Pharmaceuticals
Enzo Biochem, Inc
Tobira Therapeutics, Inc.
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF OHOLIC STEATOHEPATITIS (NASH)
1.1 Definition of oholic Steatohepatitis (NASH) in This Report
1.2 Commercial Types of oholic Steatohepatitis (NASH)
1.2.1 Weight Loss Treatment
1.2.2 Insulin-Sensitizing Agents
1.2.3 Lipid-Lowering Drugs
1.2.4 Antioxidants
1.2.5 Other Agents
1.3 Downstream Application of oholic Steatohepatitis (NASH)
1.3.1 Hospital
1.3.2 Clinics
1.3.3 Drug Store
1.3.4 Research institute
1.3.5 Others
1.4 Development History of oholic Steatohepatitis (NASH)
1.5 Market Status and Trend of oholic Steatohepatitis (NASH) 2013-2023
1.5.1 EMEA oholic Steatohepatitis (NASH) Market Status and Trend 2013-2023
1.5.2 Regional oholic Steatohepatitis (NASH) Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of oholic Steatohepatitis (NASH) in EMEA 2013-2017
2.2 Consumption Market of oholic Steatohepatitis (NASH) in EMEA by Regions
2.2.1 Consumption Volume of oholic Steatohepatitis (NASH) in EMEA by Regions
2.2.2 Revenue of oholic Steatohepatitis (NASH) in EMEA by Regions
2.3 Market Analysis of oholic Steatohepatitis (NASH) in EMEA by Regions
2.3.1 Market Analysis of oholic Steatohepatitis (NASH) in Europe 2013-2017
2.3.2 Market Analysis of oholic Steatohepatitis (NASH) in Middle East 2013-2017
2.3.3 Market Analysis of oholic Steatohepatitis (NASH) in Africa 2013-2017
2.4 Market Development Forecast of oholic Steatohepatitis (NASH) in EMEA 2018-2023
2.4.1 Market Development Forecast of oholic Steatohepatitis (NASH) in EMEA 2018-2023
2.4.2 Market Development Forecast of oholic Steatohepatitis (NASH) by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of oholic Steatohepatitis (NASH) in EMEA by Types
3.1.2 Revenue of oholic Steatohepatitis (NASH) in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of oholic Steatohepatitis (NASH) in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of oholic Steatohepatitis (NASH) in EMEA by Downstream Industry
4.2 Demand Volume of oholic Steatohepatitis (NASH) by Downstream Industry in Major Countries
4.2.1 Demand Volume of oholic Steatohepatitis (NASH) by Downstream Industry in Europe
4.2.2 Demand Volume of oholic Steatohepatitis (NASH) by Downstream Industry in Middle East
4.2.3 Demand Volume of oholic Steatohepatitis (NASH) by Downstream Industry in Africa
4.3 Market Forecast of oholic Steatohepatitis (NASH) in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF OHOLIC STEATOHEPATITIS (NASH)
5.1 EMEA Economy Situation and Trend Overview
5.2 oholic Steatohepatitis (NASH) Downstream Industry Situation and Trend Overview
CHAPTER 6 OHOLIC STEATOHEPATITIS (NASH) MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of oholic Steatohepatitis (NASH) in EMEA by Major Players
6.2 Revenue of oholic Steatohepatitis (NASH) in EMEA by Major Players
6.3 Basic Information of oholic Steatohepatitis (NASH) by Major Players
6.3.1 Headquarters Location and Established Time of oholic Steatohepatitis (NASH) Major Players
6.3.2 Employees and Revenue Level of oholic Steatohepatitis (NASH) Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 OHOLIC STEATOHEPATITIS (NASH) MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Boehringer Ingelheim
7.1.1 Company profile
7.1.2 Representative oholic Steatohepatitis (NASH) Product
7.1.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim
7.2 Cerenis Therapeutics
7.2.1 Company profile
7.2.2 Representative oholic Steatohepatitis (NASH) Product
7.2.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Cerenis Therapeutics
7.3 Connexios Life Sciences
7.3.1 Company profile
7.3.2 Representative oholic Steatohepatitis (NASH) Product
7.3.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Connexios Life Sciences
7.4 Genfit
7.4.1 Company profile
7.4.2 Representative oholic Steatohepatitis (NASH) Product
7.4.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Genfit
7.5 Islet Sciences
7.5.1 Company profile
7.5.2 Representative oholic Steatohepatitis (NASH) Product
7.5.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Islet Sciences
7.6 Nimbus Therapeutics
7.6.1 Company profile
7.6.2 Representative oholic Steatohepatitis (NASH) Product
7.6.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Nimbus Therapeutics
7.7 Verva Pharmaceuticals
7.7.1 Company profile
7.7.2 Representative oholic Steatohepatitis (NASH) Product
7.7.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Verva Pharmaceuticals
7.8 Viking Therapeutics
7.8.1 Company profile
7.8.2 Representative oholic Steatohepatitis (NASH) Product
7.8.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Viking Therapeutics
7.9 Astazeneca Plc
7.9.1 Company profile
7.9.2 Representative oholic Steatohepatitis (NASH) Product
7.9.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Astazeneca Plc
7.10 Galmed Pharmaceuticals Ltd.
7.10.1 Company profile
7.10.2 Representative oholic Steatohepatitis (NASH) Product
7.10.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Galmed Pharmaceuticals Ltd.
7.11 GENFIT SA
7.11.1 Company profile
7.11.2 Representative oholic Steatohepatitis (NASH) Product
7.11.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of GENFIT SA
7.12 Gilead Science
7.12.1 Company profile
7.12.2 Representative oholic Steatohepatitis (NASH) Product
7.12.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Gilead Science
7.13 Novo Nordisk
7.13.1 Company profile
7.13.2 Representative oholic Steatohepatitis (NASH) Product
7.13.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Novo Nordisk
7.14 Immuron Ltd
7.14.1 Company profile
7.14.2 Representative oholic Steatohepatitis (NASH) Product
7.14.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Immuron Ltd
7.15 Intercepts Pharmaceuticals
7.15.1 Company profile
7.15.2 Representative oholic Steatohepatitis (NASH) Product
7.15.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Intercepts Pharmaceuticals
7.16 Enzo Biochem, Inc
7.17 Tobira Therapeutics, Inc.
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF OHOLIC STEATOHEPATITIS (NASH)
8.1 Industry Chain of oholic Steatohepatitis (NASH)
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF OHOLIC STEATOHEPATITIS (NASH)
9.1 Cost Structure Analysis of oholic Steatohepatitis (NASH)
9.2 Raw Materials Cost Analysis of oholic Steatohepatitis (NASH)
9.3 Labor Cost Analysis of oholic Steatohepatitis (NASH)
9.4 Manufacturing Expenses Analysis of oholic Steatohepatitis (NASH)
CHAPTER 10 MARKETING STATUS ANALYSIS OF OHOLIC STEATOHEPATITIS (NASH)
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of oholic Steatohepatitis (NASH) in This Report
1.2 Commercial Types of oholic Steatohepatitis (NASH)
1.2.1 Weight Loss Treatment
1.2.2 Insulin-Sensitizing Agents
1.2.3 Lipid-Lowering Drugs
1.2.4 Antioxidants
1.2.5 Other Agents
1.3 Downstream Application of oholic Steatohepatitis (NASH)
1.3.1 Hospital
1.3.2 Clinics
1.3.3 Drug Store
1.3.4 Research institute
1.3.5 Others
1.4 Development History of oholic Steatohepatitis (NASH)
1.5 Market Status and Trend of oholic Steatohepatitis (NASH) 2013-2023
1.5.1 EMEA oholic Steatohepatitis (NASH) Market Status and Trend 2013-2023
1.5.2 Regional oholic Steatohepatitis (NASH) Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of oholic Steatohepatitis (NASH) in EMEA 2013-2017
2.2 Consumption Market of oholic Steatohepatitis (NASH) in EMEA by Regions
2.2.1 Consumption Volume of oholic Steatohepatitis (NASH) in EMEA by Regions
2.2.2 Revenue of oholic Steatohepatitis (NASH) in EMEA by Regions
2.3 Market Analysis of oholic Steatohepatitis (NASH) in EMEA by Regions
2.3.1 Market Analysis of oholic Steatohepatitis (NASH) in Europe 2013-2017
2.3.2 Market Analysis of oholic Steatohepatitis (NASH) in Middle East 2013-2017
2.3.3 Market Analysis of oholic Steatohepatitis (NASH) in Africa 2013-2017
2.4 Market Development Forecast of oholic Steatohepatitis (NASH) in EMEA 2018-2023
2.4.1 Market Development Forecast of oholic Steatohepatitis (NASH) in EMEA 2018-2023
2.4.2 Market Development Forecast of oholic Steatohepatitis (NASH) by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of oholic Steatohepatitis (NASH) in EMEA by Types
3.1.2 Revenue of oholic Steatohepatitis (NASH) in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of oholic Steatohepatitis (NASH) in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of oholic Steatohepatitis (NASH) in EMEA by Downstream Industry
4.2 Demand Volume of oholic Steatohepatitis (NASH) by Downstream Industry in Major Countries
4.2.1 Demand Volume of oholic Steatohepatitis (NASH) by Downstream Industry in Europe
4.2.2 Demand Volume of oholic Steatohepatitis (NASH) by Downstream Industry in Middle East
4.2.3 Demand Volume of oholic Steatohepatitis (NASH) by Downstream Industry in Africa
4.3 Market Forecast of oholic Steatohepatitis (NASH) in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF OHOLIC STEATOHEPATITIS (NASH)
5.1 EMEA Economy Situation and Trend Overview
5.2 oholic Steatohepatitis (NASH) Downstream Industry Situation and Trend Overview
CHAPTER 6 OHOLIC STEATOHEPATITIS (NASH) MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of oholic Steatohepatitis (NASH) in EMEA by Major Players
6.2 Revenue of oholic Steatohepatitis (NASH) in EMEA by Major Players
6.3 Basic Information of oholic Steatohepatitis (NASH) by Major Players
6.3.1 Headquarters Location and Established Time of oholic Steatohepatitis (NASH) Major Players
6.3.2 Employees and Revenue Level of oholic Steatohepatitis (NASH) Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 OHOLIC STEATOHEPATITIS (NASH) MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Boehringer Ingelheim
7.1.1 Company profile
7.1.2 Representative oholic Steatohepatitis (NASH) Product
7.1.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim
7.2 Cerenis Therapeutics
7.2.1 Company profile
7.2.2 Representative oholic Steatohepatitis (NASH) Product
7.2.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Cerenis Therapeutics
7.3 Connexios Life Sciences
7.3.1 Company profile
7.3.2 Representative oholic Steatohepatitis (NASH) Product
7.3.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Connexios Life Sciences
7.4 Genfit
7.4.1 Company profile
7.4.2 Representative oholic Steatohepatitis (NASH) Product
7.4.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Genfit
7.5 Islet Sciences
7.5.1 Company profile
7.5.2 Representative oholic Steatohepatitis (NASH) Product
7.5.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Islet Sciences
7.6 Nimbus Therapeutics
7.6.1 Company profile
7.6.2 Representative oholic Steatohepatitis (NASH) Product
7.6.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Nimbus Therapeutics
7.7 Verva Pharmaceuticals
7.7.1 Company profile
7.7.2 Representative oholic Steatohepatitis (NASH) Product
7.7.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Verva Pharmaceuticals
7.8 Viking Therapeutics
7.8.1 Company profile
7.8.2 Representative oholic Steatohepatitis (NASH) Product
7.8.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Viking Therapeutics
7.9 Astazeneca Plc
7.9.1 Company profile
7.9.2 Representative oholic Steatohepatitis (NASH) Product
7.9.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Astazeneca Plc
7.10 Galmed Pharmaceuticals Ltd.
7.10.1 Company profile
7.10.2 Representative oholic Steatohepatitis (NASH) Product
7.10.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Galmed Pharmaceuticals Ltd.
7.11 GENFIT SA
7.11.1 Company profile
7.11.2 Representative oholic Steatohepatitis (NASH) Product
7.11.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of GENFIT SA
7.12 Gilead Science
7.12.1 Company profile
7.12.2 Representative oholic Steatohepatitis (NASH) Product
7.12.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Gilead Science
7.13 Novo Nordisk
7.13.1 Company profile
7.13.2 Representative oholic Steatohepatitis (NASH) Product
7.13.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Novo Nordisk
7.14 Immuron Ltd
7.14.1 Company profile
7.14.2 Representative oholic Steatohepatitis (NASH) Product
7.14.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Immuron Ltd
7.15 Intercepts Pharmaceuticals
7.15.1 Company profile
7.15.2 Representative oholic Steatohepatitis (NASH) Product
7.15.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Intercepts Pharmaceuticals
7.16 Enzo Biochem, Inc
7.17 Tobira Therapeutics, Inc.
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF OHOLIC STEATOHEPATITIS (NASH)
8.1 Industry Chain of oholic Steatohepatitis (NASH)
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF OHOLIC STEATOHEPATITIS (NASH)
9.1 Cost Structure Analysis of oholic Steatohepatitis (NASH)
9.2 Raw Materials Cost Analysis of oholic Steatohepatitis (NASH)
9.3 Labor Cost Analysis of oholic Steatohepatitis (NASH)
9.4 Manufacturing Expenses Analysis of oholic Steatohepatitis (NASH)
CHAPTER 10 MARKETING STATUS ANALYSIS OF OHOLIC STEATOHEPATITIS (NASH)
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
